Transient vision loss after major surgical procedures is a rare clinical complication. The most common etiologies are cardiac, spinal, head, and neck surgeries. There has been no report on vision loss after lung resection. A 65-year-old man was admitted to our clinic with lung cancer. Resection was performed using right upper lobectomy with no complications. Cortical blindness developed 12 hours later in the postoperative period. Results from magnetic resonance imaging and diffusion-weighted investigations were normal. The neurologic examination was normal. The blood glucose level was 92 mg/dL and blood gas analysis showed a PO of 82 mm Hg. After 24 hours, the patient began to see and could count fingers, and his vision was fully restored within 72 hours after this point. Autonomic dysfunction due to impaired microvascular structures in diabetes mellitus may induce posterior circulation dysfunction, even when the hemodynamic state is normal in the perioperative period. The physician must keep in mind that vision loss may occur after lung resection due to autonomic dysfunction, especially in older patients with diabetes mellitus.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553457 | PMC |
http://dx.doi.org/10.1055/s-0036-1571440 | DOI Listing |
Indian J Orthop
January 2025
Department of Orthopedics and Traumatology, Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey.
Background: Soft-tissue sarcoma involving the popliteal fossa remains challenging because it is difficult to achieve wide margins with limb salvage in this location. Adjuvant therapy is frequently necessary, and limb function can be adversely affected. We reviewed our experience with these tumors.
View Article and Find Full Text PDFFront Cell Infect Microbiol
December 2024
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Objective: We aimed to identify the diagnostic value of next-generation sequencing (NGS) of bronchoalveolar lavage fluid (BALF) from patients with non-small-cell lung cancer (NSCLC).
Methods: Forty patients who were initially diagnosed with pulmonary nodules were enrolled. Frozen section histology was used to identify the NSCLC cell types.
Med J Armed Forces India
December 2024
Senior Resident (Respiratory Medicine), Dr DY Patil Medical College, Hospital & Research Centre, Dr DY Patil Vidyapeeth University, Pune, India.
Solitary fibrous tumors of pleura (SFTP) are rare neoplasms derived from mesenchymal cells of the pleura. A 63-year-old male patient, laborer by profession, presented with progressive dry cough and breathlessness for one month. Clinically he had left-sided intrathoracic mass which was confirmed by CT thorax.
View Article and Find Full Text PDFTher Adv Med Oncol
December 2024
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), 700 University Avenue, 7-812, Toronto, ON M5G 2M9, Canada.
Background: Given advancements in adjuvant treatments for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)-targeted therapies, it is important to consider postoperative targeted therapies for other early-stage oncogene-addicted NSCLC. Exploring baseline outcomes for early-stage NSCLC with these rare mutations is crucial.
Objectives: This study aims to assess relapse-free survival (RFS) and overall survival (OS) in patients with resected early-stage NSCLC with rare targetable driver mutations.
J Thorac Oncol
December 2024
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:
Introduction: Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated in the NeoADAURA study (NCT04351555).
Methods: This is a single center, pilot study of patients with clinical stage IA-IIIA NSCLC (AJCC 8th edition) harboring an activating EGFR mutation (Exon 19 deletion, L858R) (NCT04816838).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!